BenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference
June 04 2024 - 12:00AM
Business Wire
BenevolentAI ("BenevolentAI" or the "Company") (Euronext
Amsterdam: BAI), a leader in applying advanced AI to accelerate
biopharma drug discovery, announces that it will participate in the
upcoming Goldman Sachs 45th Annual Global Healthcare Conference,
11-13 June 2024 in Miami, US.
Dr Joerg Moeller MD, Chief Executive Officer, and Catherine
Isted ACMA, Chief Financial Officer, are scheduled to take part in
a fireside chat at 08:40 EDT (13:40 BST) on 13 June 2024.
They will also be available throughout the conference for
meetings on-site and adjacent to the programme (see contact details
below).
About BenevolentAI
At BenevolentAI (AMS: BAI), we serve patients by leveraging our
proprietary and validated Benevolent Platform™ that integrates AI
and science to uncover new biology, predict novel targets and
develop first-in-class or best-in-class drugs for complex diseases.
By applying proprietary advanced AI tools, in combination with
in-house scientific expertise and wet-lab facilities, BenevolentAI
is well-positioned to identify and accelerate novel drug
discovery.
The Company’s business model presents multiple routes for value
creation including discovery collaborations with pharma companies
like AstraZeneca and Merck and advancing in-house pipelines to
inflection points. Headquartered in London, with wet labs in
Cambridge (UK), BenevolentAI is at the forefront of reshaping the
future of drug discovery and delivering innovative medicines.
Category: non-regulatory
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240603254094/en/
Enquiries:
Investors: Catherine Isted – Chief Financial Officer
investors@benevolent.ai
Media: James Osborn – Communications Lead
press@benevolent.ai
FTI Consulting: Ben Atwell/Simon Conway/Victoria Foster
Mitchell T: +44 203 727 1000 BenevolentAI@fticonsulting.com